Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
MOONRAY-01
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT06586515 ↗
- Active, not recruiting
- Eli Lilly and Company
- Focused
We haven't built an HCP commentary report on MOONRAY-01 (LY3962673, cetuximab and 6 more in Pancreatic Ductal Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MOONRAY-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer
- Interventions
- LY3962673; Cetuximab; Gemcitabine; nab-paclitaxel; Oxaliplatin; leucovorin; Irinotecan; 5-fluorouracil
- Arms
- Phase 1a: LY3962673 Dose Escalation · Experimental
- Phase 1b: LY3962673 Dose Expansion · Experimental
- Experimental: Phase 1a: LY3962673 Monotherapy · Experimental
- Enrollment
- 630 (estimated)
- Primary outcomes
- Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
- Phase 1a: Number of Participants with DLT
- Phase 1a: Number of Participants with DLT Equivalent Toxicities
- Phase 1b: Overall Response Rate (ORR)
- Phase 1b: Best Overall Response (BOR)
- Phase 1b: Duration of Response (DOR)
- Phase 1b: Time to Response (TTR)
- Phase 1b: Disease Control Rate (DCR)
- Sponsor
- Eli Lilly and Company
- Start
- Sep 12, 2024
- Primary completion
- Mar 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06586515 · updated Oct 20, 2026